-Myc is a proto-oncogenic transcription factor and its rapid turnover mediated by the ubiquitin-proteasome system is critical for maintaining normal cellular homeostasis. Multiple ubiquitin ligases have been assigned for c-Myc regulation till date. However, the available data suggest for the possible existence of additional E3 ligase(s). Here, we report a new E3 ligase for c-Myc, the carboxyl terminus of Hsc70-interacting protein or CHIP, which is a chaperone-associated Ubox-containing E3 ligase. In this report, we show that CHIP interacts and ubiquitinates c-Myc, thus targeting it for proteasome-mediated degradation. Overexpression of CHIP could accelerate the turnover rate of c-Myc protein. Conversely, knockdown of CHIP by RNAi stabilizes endogenous c-Myc. The interaction between CHIP and c-Myc depends on the N-terminally located tetratricopeptide repeats of CHIP, which has been implicated as a chaperone-binding motif. Inhibition of Hsp90 chaperone activity by 17-N-allylamino-17-demethoxygeldanamycin reduces c-Myc protein level. We found that the association between CHIP and c-Myc is dependent on the chaperones; particularly Hsp70. CHIP antagonizes the transcriptional activity of c-Myc and decreases the abundance of the transcripts of its target genes. Overall, CHIPknockdown increases malignant behavior of C6 glioma cells. To the best of our knowledge, this is the first report of c-Myc being regulated by a bona-fide chaperone-associated E3 ligase in HEK293 as well as glioma cells. Because CHIP has been reported earlier to be negatively regulating Akt1, BCR-ABL and hTERT, and now c-Myc, the present study may strengthen the view that CHIP acts as a tumor suppressor.
INTRODUCTION
Overexpression of c-Myc is a hallmark of human cancers. Genetic amplifications (colon cancer), insertions (cervical cancer) and translocations (Burkitt's lymphoma) of c-Myc gene were identified as the causal mechanism for aberrant overexpression of c-Myc protein. 1 Several reports have now established that in many cancers c-Myc is accumulated due to its prolonged half-life contributing to an uncontrolled proliferation of cancer cells and that the ubiquitin-proteasome system has indispensable role in regulating c-Myc. [2] [3] [4] [5] [6] Till date, six different E3 ligases have been implicated in regulating c-Myc protein stability through the ubiquitin-proteasome system: SCF Skp2 ; SCF Fbw7 ; HectH9; Huwe1; SCF bTrCP and TRUSS. Experimental loss-of-function of SCF Skp2 , SCF Fbw7 , Huwe1 and TRUSS stabilized c-Myc, whereas the functions of SCF bTrCP and HectH9 are required for c-Myc stability. TRUSS and SCF Fbw7 decrease whereas SCF Skp2 , SCFb TrCP and HectH9 increase c-Myc transactivation potential. [7] [8] [9] [10] [11] [12] [13] Furthermore, the stabilizing mutations of c-Myc observed in some cancers have not been documented in most others, like certain cases of human glioma. Thus, c-Myc turnover is complex and is critically determined by multiple mechanisms that are likely to differ under different cellular contexts. 3, 6 Overexpressed c-Myc has been shown to colocalize with Hsp70 in the nucleus of COS, HeLa, HEK293 and CV1 cells.
14 However, the fate of c-Myc upon such interaction remains obscure. Endogenous Hsp90 was shown to physically interact with c-Myc and was found to be tethered to c-Myc transcription complex on the Connexin43 (Cx43) promoter in NIH3T3-Ras-transformed cells. Treatment with geldanamycin reduced c-Myc-driven transcription of Cx43 promoter-luciferase reporter. 15 Interestingly, the possibility of a direct involvement of the chaperones in regulating c-Myc protein stability has not been explored.
Carboxyl terminus of Hsc70-interacting protein (CHIP) links the chaperone and the 26S proteasome machinery by ubiquitinating chaperone substrates and channeling them towards proteasome. 16 Several independent reports have now established that the observed downregulation of many Hsp90 clients such as CFTR, LRRK2 and RUNX2 upon 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) (a derivative of geldanamycin) treatment is in large part dependent on CHIP activity. [17] [18] [19] [20] These observations prompted us to ask whether c-Myc protein stability is also affected as a result of its partnership with the chaperones and whether CHIP can act as an E3 ligase of c-Myc in this context.
In this report, we show that CHIP interacts with and ubiquitinates c-Myc, thus behaving as a critical determinant of c-Myc half-life and transcriptional activity. Thus, CHIP can be a potentially valid candidate for treating c-Myc-driven cancers.
RESULTS
CHIP regulates both endogenously and exogenously expressed c-Myc protein stability c-Myc protein regulation is controlled by multiple E3 ligases acting under different cellular contexts with different outcomes in terms of its stability and transactivation potential. Because the chaperone machinery is known to be sensitive to cellular c-Myc levels we entertained the idea that CHIP may be involved. To investigate the possibility that CHIP regulates c-Myc, we first examined the effect of overexpression of CHIP on both endogenously and exogenously expressed c-Myc protein. We observed that CHIP could decrease c-Myc in a dose-dependent manner in HEK293 cells (Figure 1a ). CHIP-WT but not its mutants (CHIP-K30A and CHIP-H260Q) were found to decrease endogenous c-Myc (Figure 1b) . The K30A mutation in the tetratricopeptide repeats (TPR) domain of CHIP disrupts interaction with Hsp70/90 chaperones and the H260Q mutation in the Ubox domain abolishes its E3 ligase activity. Similar results were also obtained when c-Myc was overexpressed along with CHIP and its mutants, indicating that CHIP decreases constitutively expressed c-Myc protein ( Figure 1c ) in a manner dependent on its chaperone binding and E3 ligase activity. Employing a converse approach, we depleted endogenous CHIP in HEK293 cells using small interfering RNA (siRNA) duplexes and found a clear increase in the level of endogenous c-Myc (Figure 1d ). To verify our findings in a cancer cell line we either overexpressed or depleted CHIP in T98G glioma cells and observed an inverse correlation between CHIP and c-Myc in this human glioma cell line (Figure 1e ).
CHIP physically associates with c-Myc through TPR domain Having seen that CHIP could regulate c-Myc protein stability, we next asked whether these two proteins can interact. Exogenous CHIP was readily detected in exogenous c-Myc pull-down complexes and vice versa in HEK293 cells (Figures 2a and b) . This interaction was confirmed by showing that endogenous CHIP could be found in immunocomplexes of endogenous c-Myc in HEK293 cells. However, we could detect this interaction only when c-Myc was stabilized upon proteasome inhibition by treatment with MG132 (Figure 2c ). Because the kinetics of association of CHIP with various chaperone clients changes dramatically upon induction of stress, we were interested to see what happens to the interaction of CHIP and c-Myc in the setting of cellular stress. For this, T98G cells were treated with MG132 and then either exposed to heat-shock (HS) or left alone (Figure 2d ). Immunoblot analysis for c-Myc and CHIP expression revealed that c-Myc was stabilized upon MG132 treatment as expected. Soluble CHIP levels dramatically decreased after HS, whereas MG132 treatment for the observed time-window did not elicit any detectable change. Immunoprecipitation with anti-c-Myc antibody demonstrated that CHIP and c-Myc interact in presence of both MG132 and/or HS. Interestingly, the amount of CHIP co-immunoprecipitating with c-Myc was maximal when cells were heat-shocked in presence of MG132 (Figure 2d) .
The structure of CHIP comprises of three well-characterized domains (Figure 2e ). To map the specific region of CHIP required for its interaction with c-Myc, various truncated forms of CHIP were co-expressed with full-length c-Myc and subjected to immunoprecipitation using anti-c-Myc antibody (Figure 2f ). Our results show that the TPR motifs of CHIP are necessary and sufficient for its interaction with c-Myc.
We next analyzed the cellular localization of CHIP and c-Myc by immunofluorescence studies in DBTRG glioma cells to examine whether CHIP colocalizes with c-Myc in these cells. CHIP displayed a more-or-less unbiased distribution whereas c-Myc was predominantly nuclear. We found that a portion of both c-Myc and CHIP co-occupy cellular space in these cells (Figure 2g ). Collectively, these findings support a physiological association between CHIP and c-Myc.
CHIP ubiquitinates c-Myc for its degradation As CHIP is an E3 ligase and having shown its association with c-Myc, we speculated that c-Myc might be a substrate of CHIP. To examine this we undertook in vivo ubiquitination experiments in HEK293 cells transiently overexpressing FLAG-tagged CHIP-WT, CHIP-DTPR or CHIP-DUbox together with c-Myc-myc-his and ubiquitin (Ub). CHIP-WT but not CHIP-DTPR could incorporate poly-Ub chains into c-Myc (Figure 3a) . If TPR is the interacting motif between CHIP and c-Myc this observation is expected. Surprisingly, CHIP-DUbox (lacking the E3 ligase Ubox domain) was still able to increase the ubiquitinated forms of c-Myc. If CHIP-mediated ubiquitination leads c-Myc towards proteasomal degradation, then blockade of the ubiquitin-proteasome system will be expected to stabilize ubiquitin-c-Myc conjugates. Indeed, treatment of HEK293 cells overexpressing CHIP, c-Myc and Ub with MG132 stabilized the ubiquitinated forms of c-Myc (Figure 3b) . Furthermore, c-Myc displayed enhanced ubiquitination by CHIP in a dose-dependent manner (Figure 3c ). Overexpressed CHIP could efficiently incorporate polyubiquitin chains comprising Ub-WT but not Ub-KO, which lacks all internal lysine residues (Figure 3d ). On the basis of these data we propose that CHIP-mediated poly-ubiquitination of c-Myc targets it to the proteasomal degradation pathway.
The next question we asked was whether CHIP can modulate the turnover rate of c-Myc. In HEK293 cells, exogenously expressed c-Myc had a half-life of B20 min under conditions when de novo protein synthesis had been blocked by treatment with cycloheximide (CHX) (Figure 3e, left panel) . However, the half-life of c-Myc was reduced to B10 min under otherwise similar conditions except when CHIP was overexpressed alongside (Figure 3e To see whether there exist a direct correlation between physiologic levels of c-Myc and CHIP we measured their steadystate expression levels in a panel of various cancer cell lines (Figure 3f ). Immunoblot analysis apparently do not suggest a direct negative relationship between c-Myc and CHIP, which is not surprising, given the fact that c-Myc is regulated by a number of different E3 ligases. However, as an extension to this observation we chose DBTRG and T98G glioblastoma multiforme cells to represent systems with low and high CHIP expression, respectively, and treated them with CHX to monitor c-Myc protein halflife (Figure 3g) . Coincidentally, c-Myc turnover was faster in T98G as compared with DBTRG. Altogether, these observations show that CHIP poly-ubiquitinates c-Myc, marking it for proteasomal degradation and thus can regulate its stability.
CHIP and Hsp70/90 regulate c-Myc in an interdependent manner CHIP has been reported to ubiquitinate many chaperone clients targeting them for proteasomal degradation. We wanted to determine what roles molecular chaperones have in manipulating c-Myc stability and whether CHIP has any functional role in this context. To see this we first blocked Hsp90 function using increasing doses of 17-AAG (Figure 4a ) and observed a typical HS response manifested by an upregulation of Hsp70 and Hsp90, as reported earlier. 21, 22 Concomitant with this, we also observed a dosedependent decline in c-Myc level, which is to be expected if Hsp90 behaves as a functional chaperone for c-Myc. Overexpressing CHIP in presence of 17-AAG elicited a weak additive effect ( Figure 4b ). However, siRNA-mediated knockdown of CHIP abrogated the effect of 17-AAG treatment on c-Myc (Figure 4c ).
To understand this in more detail we overexpressed c-Myc and CHIP or its mutants (CHIP-DTPR and CHIP-K30A) compromised for their interaction with chaperones in HEK293 cells and analyzed nickel-nitrilotriacetic acid (Ni-NTA) pull-down complexes for c-Myc, CHIP, Hsp70 and Hsp90 by immunoblotting (Figure 4d ). CHIP was readily detected whereas CHIP-DTPR was totally absent. CHIP-K30A interacted very weakly with c-Myc, which may be attributed to its weak association with endogenous CHIP. Interestingly, we found that Hsp70 co-precipitated with c-Myc to a much greater extent than Hsp90. Also, we did not find any alteration in the interaction between c-Myc and the chaperones upon CHIP overexpression.
Our observations showing physical interaction between c-Myc, CHIP and the chaperones prompted us to see whether they share time in the same complex with each other in intact cells. To determine this we analyzed the cellular localization of CHIP, c-Myc, Hsp70 and Hsp90 by immunofluorescence studies in DBTRG cells to examine whether they exhibit co-localization ( Figure 4e) . As previously noted, CHIP displayed an unbiased distribution, whereas c-Myc was predominantly nuclear. Under the conditions of the experiments, we observed a slight nuclear tendency for Hsp90 whereas Hsp70 showed an even distribution. The colocalization between CHIP and Hsp70 or Hsp90 did not seem to be compartment-specific, whereas the co-localization between c-Myc and Hsp70 or Hsp90 was more evident in the nucleus than in the cytoplasm possibly because of the fact that c-Myc is predominantly a nuclear protein. All of these data indicate that CHIP and the chaperones have interdependent roles in c-Myc degradation.
CHIP-mediated c-Myc turnover is independent of T58A and A44V mutations Although rare in other cancers, several stabilizing mutations associated with Burkitt's lymphoma have been described for c-Myc. T58A and A44V are point mutations that extend c-Myc halflife to B2 h and B1 h, respectively. 3, 23, 24 To investigate whether c-Myc degradation by CHIP is affected by these mutations we treated HEK293 cells transiently overexpressing either of these mutants with 17-AAG and observed a decrease in both c-Myc-T58A and c-Myc-A44V levels comparable to that of wild-type c-Myc (Figure 5a ). Similar results were obtained upon CHIP overexpression (Figure 5b ). To test whether c-Myc-T58A and A44V can still undergo poly-ubiquitination catalyzed by CHIP we undertook in vivo ubiquitination experiments in HEK293 cells transfected with either of these mutants and HA-ubiquitin together with CHIP-WT-FLAG in the absence or presence of MG132 (Figures 5c and d) . Pull-down with Ni-NTA resin revealed that both of these mutants behaved as substrates of CHIP. Furthermore, the increase in higher molecular weight ubiquitinated forms of these mutants upon MG132 treatment indicates that they indeed are channeled to the 26S proteasomal system for degradation. Taken together, these data suggest that CHIP- Lysates were incubated with Ni-NTA resin and precipitates were subjected to SDS-PAGE followed by IB with anti-Hsp90, anti-Hsp70, anti-c-Myc and anti-FLAG antibodies. (e) Co-localization of chaperones and CHIP with c-Myc. DBTRG cells were fixed and incubated with a cocktail of primary antibodies against c-Myc or CHIP together with either Hsp90 or Hsp70 followed by secondary antibodies conjugated with AF488 (green) or AF594 (red) and observed under immunofluorescence microscope. The nuclei were stained with 4,6-diamino-2-phenylindole (blue). All pictures were taken at 600X magnification. mediated poly-ubiquitination and degradation of c-Myc is independent of T58A and A44V mutations.
CHIP decreases c-Myc-dependent transcription and cell cycle progression c-Myc is an active transcription factor with B15% of the entire human genome under its control. 25 Because CHIP could decrease c-Myc protein levels we asked how it affects the transactivation potential of c-Myc. First, we measured mRNA levels of well-known c-Myc target genes using quantitative real-time PCR (qPCR) analysis upon CHIP overexpression in HEK293 cells and found significant reductions in their relative expressions (Figure 6a) . Further, to verify this observation we used a c-Myc responsive luciferase reporter and measured c-Myc transactivation in response to CHIP overexpression. As shown in Figures 6b and c , overexpression of c-Myc in HEK293 cells induced a B3.5-fold transactivation of the reporter, whereas overexpression of CHIP alone reduced promoter activity below the basal level (presumably by decreasing endogenous c-Myc protein level) in a dosedependent manner. Overexpression of CHIP-WT-FLAG but not CHIP-DTPR-FLAG compromised transactivation potential of c-Myc. Next, we wanted to determine whether the CHIP-c-Myc interplay can affect cell cycle progression in HEK293 cells. Using fluorescence-activated cell sorter (FACS) analysis we demonstrate that c-Myc can accelerate cell cycle when overexpressed, whereas CHIP significantly slows down cell cycle in a dose-dependent manner when exogenously expressed either alone or together with c-Myc (Figure 6d ). These results indicate that CHIP can antagonize c-Myc transcriptional activity and cell cycle progression in HEK293 cells.
CHIP is downregulated in rat glioma orthotopic tumor A major proportion (74%) of glioma cases displays elevated expression patterns for a core set of genes including EGFR, ErbB2, FoxO1a and Akt. 26 Interestingly, almost all of them have been shown to be targeted by CHIP for degradation. [27] [28] [29] [30] As in this report we propose c-Myc to be a substrate of CHIP, we were interested to examine the relative levels of CHIP and c-Myc in normal vs glioma tissues. For this we decided to use the rat C6 glioma cell line and Sprague-Dawley rats as a syngenic model. Orthotopic tumors formed by C6 glioma cells exhibit closest morphological resemblance to human glioblastoma multiforme and have the advantage over simplified models that inflammatory and vascular mechanisms are activated. The model has been extensively discussed previously. 31 Sections were prepared from C6-derived tumors such that they carry an adjacent portion of normal tissue to eliminate handling variations (Figure 7a ). To delineate normal from cancerous region, sections were subjected to haematoxylin and eosin (H&E) staining and gross morphological features were examined (Figure 7b ). In parallel, we examined the expression of PCNA, GFAP, c-Myc and CHIP using immunohistochemical staining procedure. Approximately 2.3-fold increase in PCNA expression and B5-fold in c-Myc expression was found in tumor region as compared with the normal (Figure 7c ; 1st and 2nd column). We could not detect any GFAP reactivity in the tumor portion agreeing with previous reports (Figure 7c ; 3rd column). 32, 33 As per our hypothesis we found a marked decrease in CHIP levels (more than B25-fold) in tumor portion as compared with the normal region (Figure 7c ; 4th column). To determine whether the observed downregulation of CHIP was at the protein or at the transcript level we performed qPCR analysis of RNA isolated from cultured normal rat astrocytes (NRA) and C6 cells. We found an B30% decrease in CHIP mRNA levels in C6 cells compared with NRA (Figure 7d ). These findings were also supported by western blot results (Figures 7e and f) . All these data cumulatively suggest that CHIP is significantly downregulated in tumor microenvironment, and may contribute at least partially to the stabilization of c-Myc, in rat C6 glioma model. CHIP loss-of-function promotes metastatic potential of rat C6 glioma cells On the basis of the observation that expression of CHIP is reduced in C6 cell-derived glioma we hypothesized that CHIP may act as a general tumor suppressor gene. Stable CHIP-knockdown C6 cells were generated by transfecting pMKO.1 vector containing either ratspecific CHIP-shRNA or a scrambled-shRNA, and selected against puromycin (1.28 mg/ml). Efficiency of knockdown was evaluated by immunoblot analysis, which established significant downregulation of CHIP protein (Figure 8a ). To determine whether CHIP downregulation alters the anchorage-independent growth of C6 cells we performed soft-agar colony-formation assay and observed a marked difference in the number of colony-forming units. CHIP-knockdown potentiated neurosphere-forming capacity by B2.8-fold as compared with control cells (Figure 8b, left panel, Po0.05 ). In addition, on an average, CHIP-sh cells formed relatively bigger colonies as compared with control cells (Figure 8b , right panel, Po0.06). We also performed 2-dimensional wound-healing assay to test the migratory behavior of C6 cells. CHIP-depleted cells (designated as CHIP-sh) 'healed' the cell-free clearing produced by the scratch faster than control cells (designated as control-sh), indicating an increased migration rate (Figure 8c ). These data demonstrate that CHIP acts as a negative regulator of oncogenic growth.
DISCUSSION
This study identifies CHIP as a novel E3 ligase of c-Myc that ubiquitinates and degrades c-Myc as well as reduces its transcriptional activity. Unlike all the previously reported E3 ligases implicated in c-Myc regulation, CHIP is the only Uboxcontaining and chaperone-associated protein.
We show that CHIP and c-Myc can co-exist in the same complex and the TPR domain of CHIP was necessary for their interaction. c-Myc was found to be a substrate for the E3 ligase activity of wildtype CHIP but not CHIP-DTPR. Interestingly, CHIP lacking the Ubox domain (CHIP-DUbox) was still able to increase the ubiquitinated forms of c-Myc. Similar results were also observed previously for LRRK2 and RUNX2. 19, 20 A possible explanation would be the involvement of other factors in the ubiquitination process; Skp2 and Parkin are promising candidates at this point. 34, 35 However, the observation that CHIP-K30A and CHIP-H260Q mutants were unable to degrade exogenous c-Myc as efficiently as CHIP-WT suggests that the E3 ligase activity of CHIP is indeed required for the degradation of c-Myc whereby the function(s) of other factors may be auxiliary. Interestingly, overexpression of CHIP-H260Q and CHIP-K30A caused a slight increase in c-Myc protein level. It has been suggested that the H260Q mutant of CHIP behaves as a dominant negative form. 36 The stabilization of c-Myc observed upon overexpression of CHIP-K30A may be due to an indirect mechanism such as heterodimerization and sequestration of endogenous CHIP by overexpressed CHIP-K30A. 37 Overexpression of CHIP increases poly-ubiquitination of c-Myc subsequently targeting it to 26S proteasomes as indicated by an increased ubiquitin-c-Myc conjugates in presence of MG132. We found that overexpressed CHIP accelerates the rate of c-Myc degradation, whereas knockdown of CHIP using RNAi approach stabilizes endogenous c-Myc. We did not find any difference in the response of CHIP towards T58A and A44V mutants as opposed to wild-type c-Myc. Our data demonstrates that CHIP-mediated degradation of c-Myc antagonizes c-Myc transcriptional activity and reduces the mRNA levels of well-known c-Myc targets. Because CHIP is a chaperone-associated ubiquitin ligase we wanted to assess the involvement of Hsp70 and Hsp90 in this mechanism. Treatment with 17-AAG elicited a typical HS response with a concomitant reduction of c-Myc levels. Our co-immunoprecipitation experiments revealed a very weak interaction between c-Myc and Hsp90. On the other hand, the interaction between c-Myc and Hsp70 was much stronger, suggesting that the association between c-Myc and Hsp90 may be transient in nature and that the Hsp70-bound pool of CHIP may be more important for c-Myc degradation. Our data may also reflect the fact that there are B10-fold more CHIP molecules bound to Hsp70 than to Hsp90 at a particular time. All these observations are in agreement with a recent report. 38 The response of overexpressed CHIP towards exogenous c-Myc was found to be much stronger than on endogenous c-Myc. Explanation may lie in the fact that Hsp70 has been known to be extremely sensitive to cellular c-Myc levels particularly when overexpressed.
14 Again this is in-line with the findings of Kundrat et Nevertheless, these findings have important implications for cancer. Our study has shown c-Myc to be a target of CHIP. In general, CHIP may act as a tumor suppressor because knockdown of CHIP in C6 rat glioma cells enhances some of their metastatic properties. Also, a recent study has found negative correlation between CHIP levels and the malignancy of human breast tissues. 39 To verify this we first compared CHIP mRNA levels between normal brain tissue and glioma using the Oncomine database, which is a publicly available cancer gene expression data sets repository. All 3 of the 3 data sets describing analyses of glioblastoma vs normal (classified under brain and CNS cancer vs normal) showed that STUB1 (CHIP) is significantly downregulated in glioblastoma with respect to normal tissue (p ¼ 0.071). Analysis of the gene rank ordered by underexpression (fold change) in these data sets (Sun brain, Lee brain and Liang brain) showed that STUB1 is among the top 3, 15 and 19% of underexpressed genes, respectively. Analysis of expression profile data set (data set name: E-GEOD-4290) using another public repository ArrayExpress ATLAS supported this finding.
In summary, our data provide compelling evidence for a significant role of CHIP in regulating c-Myc protein abundance in the cell and its transactivation potential (Figure 8d ). Our observations raise many important physiologically relevant questions such as what proportion of c-Myc is regulated by the multiplicity of mechanisms under various contexts. The ability to channel a polypeptide towards degradation pathway provides a means for the cell to dispose-off damaged, slowly folding or overexpressed proteins. Therefore, this study undermines the importance of the chaperone system in regulating protein stability and provides alternative avenues for curbing c-Myc function in cancer.
MATERIALS AND METHODS
Cell Culture, transfection and drug treatments Human cell lines: HEK293 (embryonic kidney); T98G, DBTRG-05MG (glioma); MCF7 (breast cancer); LNCaP, PC3 (prostate cancer); HCT116 (colon cancer) and rat C6 (glioma) cell lines used in the study were obtained from ATCC (Manassas, VA, USA). Cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% heat-inactivated FBS and 2000 units/l penicillin and 2 mg/l streptomycin (Invitrogen, Grand Island, NY, USA). All cells were maintained at 37 1C in a humid incubator with 5% CO 2 . Transfections of different DNA constructs were performed using either calcium phosphate protocol as described previously 40 or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. HiPerfect reagent (Qiagen, Valencia, CA, USA) was used for transfection of siRNA duplexes at a final concentration of 60 nM. The following drugs/inhibitors were used: 17-AAG, MG132, cycloheximide (CHX), puromycin (Calbiochem, Darmstadt, Germany). Concentrations used and incubation times are given in the figure legends.
Expression plasmids
The complete coding region of human CHIP (NM_005861) and c-Myc (NM_002467) were PCR amplified from total HEK293 cDNA. Full-length CHIP and two CHIP deletion mutants comprising amino acids 1-189 (CHIPDUbox) and 135-303 (CHIP-DTPR) were inserted into pIRES-hrGFP-1a using flanking primers containing EcoRI and XhoI sites to generate pIRES-CHIP-WT-FLAG; pIRES-CHIP-DUbox-FLAG and pIRES-CHIP-DTPR-FLAG. Full-length c-Myc was inserted into pcDNA3.1-myc-his using flanking primers containing XhoI and EcoRI sites to generate pcDNA3.1-c-myc-myc-his. Point mutations of CHIP (CHIP-K30A and CHIP-H260Q) and that of c-Myc (cMyc-T58A and c-Myc-A44V) were generated using the QuickChange XL Site-Directed Mutagenesis kit (Stratagene, Santa Clara, CA, USA). pRK5-HAUbiquitin-WT; pRK5-HA-Ubiquitin-KO constructs were obtained from Addgene (Cambridge, MA, USA). All constructs were verified by sequencing. Sequences of all the primers used are given in Table 1 .
RNAi knockdown siRNA against CHIP and scramble siRNA were purchased from Santacruz Biotechnology (Santa Cruz, CA, USA). Target sequences for human specific CHIP-shRNA (5 0 -AACCAAGCACGACAAGTACAT-3 0 ) and rat-specific CHIP-shRNA (5 0 -CCCTGTGCTATCTGAAGATTT-3 0 ) was selected using Whitehead Institute siRNA designing tool. Both sense and antisense oligonucleotides were synthesized by IDT (Integrated DNA Technologies, Coralville, IA, USA) according to standard protocol, annealed and inserted into pMKO.1 expression vector (Addgene) between AgeI and EcoRI sites. Control shRNA was constructed similarly except that the sequence inserted was scrambled to any known genomic loci. 41 All constructs were verified by sequencing. To prepare stable cells, transfections were done using Lipofectamine 2000 (Invitrogen) followed by selection and maintenance on puromycin (1.28 mg/ml). Effectiveness of the knockdown was verified using immunoblot analysis as shown in the corresponding figures.
Ni-NTA pull-down, immunoprecipitation and western blot analyses For pull-down using Ni-NTA (Qiagen) cells were lysed on ice in Lysis Buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM Imidazole). Lysates were incubated with 20 ml (of 50% slurry) Ni-NTA resin at 4 1C for 1 h and then washed three times with lysis buffer containing 50 mM imidazole. Complexes were eluted with lysis buffer containing 250 mM imidazole. For co-immunoprecipitation experiments, cells were lysed on ice using IP buffer (50 mM HEPES, pH 7.2, 250 mM NaCl, 10% glycerol, 1% Nonidet P-40, 1.0 mM EDTA, 0.5 mM dithiothreitol (DTT), 10 mM phenylmethanesulfonylfluoride and protease inhibitor cocktail). After pre-clearing with Protein A Sepharose beads (Amersham Biosciences, Piscataway, NJ, USA), 1 mg of total protein was subjected to immunoprecipitation as described previously. 42 For western blotting, cells were lysed on ice using Tris lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 10% Glycerol þ protease inhibitors). The following antibodies were used: GAPDH, b-actin, a-tubulin, LaminB, c-Myc (C-33) (Santacruz Biotechnology); c-Myc, myc-tag, FLAG, CHIP, Hsp90, Hsp70 (Cell Signaling Technology, Danvers, MA, USA). Densitometric scanning of immunoblots was done using the ImageJ software (Bethesda, MD, USA). Table 1 . Lists of all primers used for cloning, sub-cloning and site-directed mutagenesis of various constructs employed in this studyPrimers
Accession
Symbol Used for Primer sequences ). This interaction may be important for some aspect of c-Myc function such as transcriptional activity. For the first case, inhibition of Hsp90 or overexpression of CHIP will be expected to cause degradation of c-Myc, reducing its total cellular pool and decreasing its transcriptional activity. Consideration of the second case point towards an interesting possibility; because Hsp90 has been found on c-Myc transcription complex it will not be unreasonable to imagine that a certain fraction of CHIP might also be present on such promoters. Support for such a notion can be taken from the observation that a substantial amount of CHIP translocates to the nucleus after heat-shock and induces HSF-1 DNA binding. 45 Thus, future investigations directed towards the nuclear role of the chaperones (and CHIP) specifically in regulating the dynamics of transcription complexes is expected to yield important insights.
Quantitative real-time PCR
Total RNA was extracted using the Trizol reagent (Invitrogen). For each sample, 2 mg of RNA was converted to cDNA using High Capacity Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) and subsequently used for qPCR analysis using Power SYBR Green Master Mix on 7500 Fast Real-Time PCR system (Applied Biosystems). In all experiments, 18S rRNA served as the internal control (normalization) and calibrator controls were chosen appropriately. Sequences of all the primers used are given in Table 2 .
Luciferase assays HEK293 cells were transiently transfected with Renilla and firefly luciferase vectors along with the indicated constructs. Luciferase activity of cell lysates was determined luminometrically using the GLOMAX 20/20 luminometer (Promega, Madison, WI, USA) by the dual luciferase assay system (Promega) as specified by the manufacturer. Quantification was based on three independent experiments.
FACS analysis
Cells were scraped in phosphate-buffered saline, pelleted, resuspended in ice-cold 70% ethanol for fixation and kept for 45 min on ice. After washing in phosphate-buffered saline two times cells were resuspended in PI/RNase staining buffer (BD Pharmingen) and incubated in dark for 15 min at ambient temperature. Cell cycle distribution was examined by flow cytometry using a FACS array flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using WinMDI 2.9 software (http:// facs.scripps.edu/).
Immunofluorescence microscopy DBTRG cells were fixed with 3.7% paraformaldehyde, permeabilized with 0.5% Triton-X-100 and blocked with 3% bovine serum albumin (in phosphate-buffered saline) before incubation with primary antibodies overnight at 4 1C followed by secondary antibody for 1 h at room temperature under dark conditions. 43 Photographs were captured on Olympus BX61 motorized fluorescence microscope using Image ProPlus software (Olympus, Center Valley, PA, USA). The following antibodies were used: c-Myc, CHIP, Hsp70 and Hsp90 (Cell Signaling Technology); AF488 or AF594 (Molecular Probes, Grand Island, NY, USA).
Orthotopic tumor model
All animal care and experimentation conformed to the CPCSEA guidelines. Sprague-Dawley rats weighing B200 g received intracranial injections of early passage C6 cells (1 Â 10 5 ) once. Tissue samples of both tumor and adjacent normal region of brain were collected and fixed in 10% buffered formalin and embedded in paraffin.
Histology and immunohistochemistry
Tumor sections were processed following standard methods. Histological features were examined using routine H&E staining. For immunohistochemistry, antigen retrieval was done using standard citrate buffer protocol. The following antibodies were used: GFAP, PCNA (Cell Signaling Technology), CHIP and c-Myc (Santacruz Biotechnology).
Soft-agar colony formation, two-dimensional scratch (wound healing) assays For soft-agar assays, 2000 cells were suspended in DMEM containing 0.35% agar and layered on top of 1 ml of DMEM solidified with 1.0% agar in each 35-mm dish. After growing at 37 1C for 10 days, colonies with a diameter of 4100 mm were counted in three different microscopic fields. The migratory behavior of C6 cells were evaluated using the scratch (wound healing) assay. Briefly, equal number of cells were seeded on 6-well plates and allowed to reach confluency. Several scratches were made using a 200 ml pipette tip spanning the well. Migration of cells was observed at premarked positions below the wells using an Olympus IX81 inverted microscope at both 40X and 100X magnifications.
Statistical analysis and densitometry
All statistical calculations were done using GraphPad (QuickCalcs, http:// www.graphpad.com/quickcalcs/index.cfm) calculator. Fisher's exact test was used to compare the immunohistological results of antibody staining between normal and C6 tumor samples. For other experiments Student's t test (unpaired) was used. In all experiments a value of Po0.05 was taken as significant.
ABBREVIATIONS CHIP, carboxyl terminus of Hsc70-interacting protein; H&E, haematoxylin and eosin; 17-AAG, 17-N-allylamino-17-demethoxygeldanamycin; Ni-NTA, nickel-nitrilotriacetic acid. 
